Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OU3Q
|
|||
| Former ID |
DIB005401
|
|||
| Drug Name |
TAK-058
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Phase 1 | [1] | |
| XY disorder of sex development due to androgen resistance [ICD-11: LD2A.4; ICD-10: E34.5] | Phase 1 | [2] | ||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 3 receptor (5HT3R) | Target Info | Antagonist | [3], [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02389881) Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040805) | |||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.